@article{ref1,
title="Suicidality risk factors across the CARE-HD, 2CARE, and CREST-E clinical trials in Huntington disease",
journal="Neurology. Clinical practice",
year="2022",
author="McGarry, Andrew and Auinger, Peggy and Kieburtz, Karl D. and Bredlau, Amy-Lee and Hersch, Steven M. and Rosas, H. Diana",
volume="12",
number="2",
pages="131-138",
abstract="BACKGROUND AND OBJECTIVES: Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial. <br><br>METHODS: The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E. <br><br>RESULTS: We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality). <br><br>DISCUSSION: These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials. TRIAL REGISTRATION INFORMATION: 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.<p /> <p>Language: en</p>",
language="en",
issn="2163-0402",
doi="10.1212/CPJ.0000000000001161",
url="http://dx.doi.org/10.1212/CPJ.0000000000001161"
}